Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jan 24;11:484. doi: 10.1038/s41467-019-14186-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 7 — a Tamoxifen (TM) injection. b Western blotting. Protein extracts from isolated islets of indicated genotypes treated with TM as described in a were subjected to Western blotting. c GTT. Mice were treated with TM as described in a and fasted overnight. *P < 0.05, versus MIP-CreERT (control), ^#P < 0.05, versus K2^f/f; MIP-CreERT, N = 6 for MIP-CreERT, N = 4 for K2^f/f; MIP-CreERT and K2^f/f; MIP-CreERT; β-cat (ex)^fl/+, Student’s t test. d GSIS. Mice with indicated genotypes were treated with TM as described in a and fasted overnight. *P < 0.05, versus K2^f/f; MIP-CreERT, N = 5 for MIP-CreERT, N = 4 for K2^f/f; MIP-CreERT, and N = 6 for K2^f/f; MIP-CreERT; β-cat (ex)^fl/+. Student’s t test. e β-cell mass. After the ITT experiments, pancreatic sections were subjected to IHC staining for insulin, followed by measurements of β-cell mass. *P < 0.05, versus MIP-CreERT (control), ^#P < 0.05, versus K2^f/f; MIP-CreERT. N = 5 for MIP-CreERT, N = 4 for K2^f/f; MIP-CreERT, and N = 7 for K2^f/f; MIP-CreERT; β-cat (ex)^fl/+. Student’s t test. f ITT. Mice with indicated genotypes were treated with TM as described in a and fasted (6–7 h), followed by performance of ITT assays. N = 7 for control, N = 4 for K2^f/f; MIP-CreERT and K2^f/f; MIP-CreERT; β-cat (ex)^fl/+. g Insulin secretion. One-month-old male MIP-CreERT, K2^f/f; MIP-CreERT and K2^f/f; MIP-CreERT; β-cat (ex)^fl/+ mice were injected with TM as described in a. One month after the last TM injection, islets were isolated from each group and treated with 2.8 or 16.7 mM glucose or 20 mM KCl. Amounts of insulin in supernatant were measured by enzyme-linked immunosorbent assay (ELISA). Insulin secretion was measured as described in Fig. 2f. *P < 0.05, versus control (MIP-CreERT), Student’s t test. Results are expressed as mean ± standard deviation. h A working model for Kindlin-2 regulation of β cell function. Source data for b–g are provided as a Source Data file.